BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bepranemab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bepranemab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04658199-687@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Bepranemab: Phase 1 readout est. (NCT04658199)
DESCRIPTION:Bepranemab\, phase 1.\nStudy: A Study to Test the Safety and To
 lerability of Long-term UCB0107 Administration in Study Participants With 
 Progressive Supranuclear Palsy\nEstimated primary completion: 13 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bepranemab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04658199
URL:https://assetmemo.bio/drug/bepranemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
